A

Amgen

Biotech company creating biologic medicines

Engineering Analytics & Bid Review

Full-TimeUpdated on 10/2/2026
No salary listed
Senior
Bachelor's, Master's
Hyderabad, Telangana, India
In Person

About the job

Requirements
  • A Bachelor's or Master's degree in a relevant field such as Computer Science or Engineering.
  • Five to nine years of work experience in Information Technology, Information Systems, or a related field.
  • Experience with project controls and analytics in a capital project, engineering, procurement, or estimating environment.
  • Experience supporting bid review, cost comparison, benchmarking, forecasting, reporting, or supplier proposal analysis.
  • Ability to review capital equipment bids and interpret cost, scope, schedule, assumptions, exclusions, delivery risks, and comparison points.
  • Experience with digital tools for reporting and analytics such as Power BI, advanced Excel, SAP, procurement or sourcing systems, data structuring, or similar platforms.
  • Understanding of data integrity, process compliance, documentation discipline, and audit readiness in project controls, analytics, or procurement-related workflows.
  • Understanding of capital project cost, schedule, procurement, and supplier delivery information.
  • Ability to partner with Engineering, Project Controls, Procurement, Finance, and project teams.
  • Relevant certification in project management, project controls, cost management, analytics, engineering, or a related discipline.
  • Ability to deliver high-quality work under timelines.
  • Flexibility to work across different shifts as required by business needs.
Responsibilities
  • Support capital equipment bid review, including cost comparison, schedule and lead-time review, scope completeness, assumptions, exclusions, and risk indicators.
  • Support benchmarking by comparing current bids against historical project and equipment data to identify cost trends, variance drivers, supplier differences, and forecasting inputs.
  • Support reporting, analytics, and decision-support tools that improve visibility into equipment demand, spend, bid comparisons, supplier risks, delivery milestones, and lifecycle status.
  • Support the equipment data foundation by collecting, validating, and maintaining bid, supplier, cost, demand, schedule, delivery, and lifecycle data.
  • Maintain audit-ready analysis files, data records, assumptions, and supporting documentation in alignment with established project controls and procurement processes.
  • Use digital, automation, and artificial-intelligence-enabled tools to improve analysis quality, reporting efficiency, data review, and insight generation.
  • Partner with Project Controls, Engineering, Procurement, Finance, and project teams to gather inputs, validate assumptions, and align analytical outputs.
  • Support bid review templates, reporting standards, analytics methods, and data quality practices.
Desired Qualifications
  • Experience in the global pharmaceutical industry.
  • Experience supporting capital projects in pharmaceutical, biotechnology, life sciences, advanced manufacturing, or other regulated industries.
  • Experience working with capital equipment, supplier bids, procurement data, or equipment lifecycle information.
  • Familiarity with artificial-intelligence-enabled productivity and analytics tools such as ChatGPT, Codex, Visual Studio Code extensions, or similar tools.
  • Experience developing bid review templates, reporting standards, data models, or analytical tools.
  • Familiarity with automation, advanced analytics, data quality improvement, or scalable reporting practices.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $39.4 billion.
  • Imdelltra sales jumped 219% year over year in Q1 2026, signaling rapid launch traction.
  • Repatha sales rose 37% in Q2 2026, driven by expanding cardiology and primary-care adoption.

What critics are saying

  • Prolia and Enbrel face accelerating biosimilar erosion; Amgen expects continued sales declines through 2026.
  • Three distributors generated 77% of gross revenue in 2026, concentrating pricing leverage brutally.
  • MariTide failure would crater obesity optionality and expose Amgen's growth to aging franchises.

What makes Amgen unique

  • September 2026 Imdelltra-IMFINZI phase III hit overall survival in first-line ES-SCLC.
  • August 2026 Repatha reduced death risk in high-risk patients, strengthening Amgen's cardiovascular moat.
  • MariTide's monthly-or-less dosing and nine Phase III studies separate it from weekly GLP-1s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.